A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Bristol-Myers Squibb
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
City of Hope Medical Center
AHS Cancer Control Alberta
City of Hope Medical Center
Emory University
National Institutes of Health Clinical Center (CC)
Myeloid Therapeutics
Atara Biotherapeutics
Memorial Sloan Kettering Cancer Center
Northwestern University
AbbVie
Mayo Clinic
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Mayo Clinic
Northwestern University
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
University of Washington
Stanford University
National Cancer Institute (NCI)
University of Michigan
Stanford University
National Cancer Institute (NCI)
Asan Medical Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Northwestern University
Northwestern University
UNC Lineberger Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Boston University